Issue link: http://www.e-digitaleditions.com/i/730359
What is the IPAC-RS Cascade Impaction Working Group? Founded in 2001, the International Pharmaceutical Aerosol Consortium for Regulation and Science (IPAC- RS) is an international association of companies that develop or manufac- ture orally inhaled and intranasal drug products (OINDPs) such as metered dose inhalers and dry pow- der inhalers. The mission of IPAC- RS is to advance scientifically driven approaches to enhancing the quality of inhaled and intranasal drug prod- ucts for the benefit of patients. To this end, a variety of working groups con- duct research on topics of interest to member companies, including the tests used for in vitro evaluation of these products. The cascade impaction (CI) working group of IPAC-RS strives to advance the theory and practice of cascade impaction. Our efforts generally fall into one of two categories: defining and encouraging adoption of CI best practices, and championing the use of Abbreviated Impaction Measure- ment (AIM) along with a novel data analysis strategy termed Efficient Data Analysis (EDA). Why create an online CI tutorial? To advance the science of cascade impaction, we have essentially two A free online tutorial about cascade impaction from the IPAC-RS CI working group Adrian P. Goodey, PhD Jolyon P. Mitchell, PhD, FRSC(UK), CChem, CSci Terrence P. Tougas, PhD Dave Christopher, MSc Svetlana A. Lyapustina, PhD On behalf of the Cascade Impaction Working Group of the International Pharmaceutical Aerosol Consortium on Regulation and Science (IPAC-RS) continued on page 30 BACK • PAGE Figure 1 From Module 1, Fundamentals of Pharmaceutical Aerosols 32 OCTOBER2016 Inhalation